The Rac1 Promoter as a Molecular Nexus for Antihypertensive Therapy Resistance and Enhanced Malaria Susceptibility.

In Sub-Saharan Africa, the escalating burden of hypertension converges with persistent malaria endemicity, creating a complex clinical challenge marked by increasing rates of resistance to first-line antihypertensive therapies, particularly angiotensin-converting enzyme inhibitors (ACEIs) and Angiotensin II receptor blockers (ARBs). The molecular mechanisms underpinning this therapeutic failure remain elusive. Rac1, a Rho GTPase regulating both cardiovascular function and erythrocyte biology, presents a compelling molecular link between these comorbidities, yet its regulatory architecture in this context is uncharacterized. We conducted a comprehensive in silico analysis of the human Rac1 promoter region (-2000 to +500 bp relative to the transcription start site) using biomaRt, BSgenome, and the JASPAR2022 database, anchored to the GRCh38/hg38 reference genome. African ancestry variants from resources such as gnomAD were considered to enhance population-specific relevance. Transcription factor binding sites were predicted using position weight matrices with an 80% relative score threshold to balance sensitivity and specificity. CpG island analysis was performed, including calculation of the observed/expected (o/e) ratio. The 2501 bp Rac1 promoter is notably GC-rich (57.34%) and contains 164 CpG sites with an o/e ratio of 0.75, defining a canonical CpG island. Analysis revealed a complex regulatory landscape featuring binding motifs for the mineralocorticoid receptor (MR), suggesting a potential pathway for bypassing RAAS blockade and contributing to ACEI/ARB resistance. Binding sites for hypoxia-inducible factors, inflammatory mediators, and the erythroid-specific factor GATA-1 were also identified. Spatial analysis showed nonrandom clustering of these elements, suggesting integrated response capabilities. The regulatory architecture of the Rac1 promoter suggests a potential molecular basis for MR-mediated resistance to ACEI/ARB therapies while simultaneously providing a predictive link to enhanced malaria susceptibility through erythrocyte remodeling pathways. These findings offer a novel framework for understanding treatment-resistant hypertension in malaria-endemic regions and identify the Rac1 promoter as a candidate nexus for developing dual-disease therapeutic strategies tailored to high-burden populations.